Antibiotic treatment of ventilator-associated tracheobronchitis: To treat or not to treat?

Current Opinion in Critical Care

Volumn 20, Issue 5, 2014, Pages 532-541

  Craven, Donald E ^a,d   Hudcova, Jana ^b,d   Craven, Kathleen A ^e   Scopa, Caitlin ^a,b   Lei, Yuxiu ^a,b,c  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b Department of Surgical Critical Care ^*  (United States)

^c Pulmonary and Critical Care Division   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Infection Prevention Consultants   (United States)

Author keywords

Appropriate antibiotics; Outcomes; Prevention; Ventilator associated pneumonia; Ventilator associated tracheobronchitis

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIAL VIRULENCE; HUMAN; INCIDENCE; MECHANICAL VENTILATOR; PATHOGENESIS; PRACTICE GUIDELINE; REVIEW; TRACHEOBRONCHITIS; VENTILATOR ASSOCIATED TRACHEOBRONCHITIS; ADVERSE EFFECTS; BRONCHITIS; COMPLICATION; CROSS INFECTION; ENDOTRACHEAL INTUBATION; INFLAMMATION; INTENSIVE CARE UNIT; MICROBIOLOGY; PATHOPHYSIOLOGY; PNEUMONIA, VENTILATOR-ASSOCIATED; PROGNOSIS; TRACHEITIS;

ANTI-BACTERIAL AGENTS; BRONCHITIS; CROSS INFECTION; HUMANS; INFLAMMATION; INTENSIVE CARE UNITS; INTUBATION, INTRATRACHEAL; PNEUMONIA, VENTILATOR-ASSOCIATED; PROGNOSIS; TRACHEITIS; VENTILATORS, MECHANICAL;

EID: 84925940003     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0000000000000130     Document Type: Review

References (46)

1. Nseir S, Di Pompeo C, Pronnier P, et al. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome. Eur Respir J 2002;20:1483-1489.
2. Nseir S, Favory R, Jozefowicz E, et al. Antimicrobial treatment for ventilatorassociated tracheobronchitis: a randomized, controlled, multicenter study. Crit Care 2008;12:R62.
3. Palmer LB, Smaldone GC, Chen JJ, et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 2008;36:2008-2013.
4. Agrafiotis M, Siempos II, Falagas ME. Frequency, prevention, outcome and treatment of ventilator-associated tracheobronchitis: systematic review and meta-analysis. Respir Med 2010;104:325-336.
5. Grgurich PE, Hudcova J, Lei Y, et al. Diagnosis of ventilator-associated pneumonia: controversies and working toward a gold standard. Curr Opin Infect Dis 2013;26:140-150.
6. American Thoracic Society Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated, pneumonia. Am J Respir Crit Care Med 2005;171:388-416; 2005.
7. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903.
8. Unroe M, Kahn JM, Carson SS, et al. One-year trajectories of care and resource utilization for recipients of prolonged mechanical ventilation: a cohort study. Ann Intern Med 2010;153:167-175.
9. Nseir S, Ader F, Marquette CH. Nosocomial tracheobronchitis. Curr Opin Infect Dis 2009;22:148-153.
10. Shorr AF, Chan CM, Zilberberg MD. Diagnostics and epidemiology in ventilator-associated pneumonia. Ther Adv Respir Dis 2011;5:121-130.
11. Craven DE, Lei Y, Ruthazer R, et al. Incidence and outcomes of ventilatorassociated tracheobronchitis and pneumonia. Am J Med 2013;126:542-549. This natural study reported a VAT rate of 21 patients (11%) of a mixed medical and surgical population ventilated more than 48 h, of which six (29%) progressed from the VAT to VAP. MDR pathogens were isolated from 39% of the VAP patents. VAT was associated with significant increase in ventilator days and length of stay in the ICU (P<0.02).
12. Craven DE, Steger KA. Nosocomial pneumonia in mechanically ventilated adult patients: epidemiology and prevention in 1996. Semin Respir Infect 1996;11:32-53.
13. Dallas J, Skrupky L, Abebe N, et al. Ventilator-associated tracheobronchitis in a mixed surgical and medical ICU population. Chest 2011;139:513-518.
14. Niederman MS. The clinical diagnosis of ventilator-associated pneumonia. Respir Care 2005;50:788-796.
15. Wunderink RG. Clinical criteria in the diagnosis of ventilator-associated pneumonia. Chest 2000;117(4 Suppl 2):191S-194S.
16. Chroneou A, Zias N, Gray A, Craven DE. Ventilator-associated pneumonia. In: O'Donnell J, Nacul F, editors. Surgical intensive care medicine, 2nd ed Springer; 2010. pp. 325-342.
17. El-Ebiary M, Torres A, Gonzalez J, et al. Quantitative cultures of endotracheal aspirates for the diagnosis of ventilator-associated pneumonia. Am Rev Respir Dis 1993;148(6 Pt 1):1552-1557.
18. Safdar N, Crnich CJ, Maki DG. The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for prevention. Respir Care 2005;50:725-739.
19. Micek ST, Heuring TJ, Hollands JM, et al. Optimizing antibiotic treatment for ventilator-associated pneumonia. Pharmacotherapy 2006;26:204-213.
20. Bouza E, Granda MJ, Hortal J, et al. Preemptive broad-spectrum treatment for ventilator-associated pneumonia in high-risk patients. Intensive Care Med 2013;39:1547-1555. This is a study of pre-emptive antibiotic therapy for VAT/VAP in high-risk patients who were randomized to a 3-day course of linezolid and meropenem that demonstrated that the intervention group had significantly lower rates of VAT/VAP/1000 days in the treated group (32 versus 65, P<0.03) and longer time to the first episode of VAT/VAP (9 versus 4.5 days, P=0.02).
21. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillinresistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012;54:621-629.
22. Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996;109:1019-1029.
23. Nseir S, Deplanque X, Di Pompeo C, et al. Risk factors for relapse of ventilator-associated pneumonia related to nonfermenting Gram negative bacilli: a case-control study. J Infect 2008;56:319-325.
24. Planquette B, Timsit JF, Misset BY, et al. Pseudomonas aeruginosa ventilatorassociated pneumonia. Predictive factors of treatment failure. Am J Respir Crit Care Med 2013;188:69-76. Excellent review of factors predictive of treatment failure for VAP due to P. aeruginosa.
25. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005;31:649-655.
26. Tasbakan MS, Pullukcu H, Ekren PK, et al. [Colistin use in ventilator-associated pneumonia due to panresistant Pseudomonas aeruginosa and Acinetobacter baumannii]. Mikrobiyol Bul 2009;43:61-70.
27. Aydemir H, Akduman D, Piskin N, et al. Colistin vs. The combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 2013;141:1214-1222.
28. Palmer LB. Ventilator-associated infection. Curr Opin Pulm Med 2009;15:230-235.
29. Kollef MH, Hamilton CW, Montgomery AB. Aerosolized antibiotics: do they add to the treatment of pneumonia? Curr Opin Infect Dis 2013;26:538-544. State-of-the-art review of the use of intravenous antibiotics plus aerosolized antibiotics to assess broad-spectrum activity against Gram-negative bacilli and MRSA.
30. Montgomery AB, Vallance S, Abuan T, et al. A randomized double-blind placebo-controlled dose-escalation Phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow inline nebulizer system in mechanically ventilated patients. J Aerosol Med Pulm Drug Deliv 2014. [Epub ahead of print] A large multicenter randomized clinical trial in which patients with VAP due to Gram-negative bacilli will be treated with intravenous antibiotics and then randomized to treatment with fosfomycin and an aminoglycoside versus a placebo using a new aerosol antibiotic in-line delivery system; outcomes will then be compared using the win-ratio method. Active and placebo groups will be compared using the 'win ratio' formula calculated on number of matched pairs in the intervention group/total number of pairs with any winner by specified endpoints: that is 28-day mortality, ventilator-free days.
31. Tablan OC, Anderson LJ, Besser R, et al. Guidelines for preventing healthcareassociated pneumonia 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004;53:1-36.
32. Silvestri L, Van Saene HK, Zandstra DF, et al. SDD, SOD, or oropharyngeal chlorhexidine to prevent pneumonia and to reduce mortality in ventilated patients: which manoeuvre is evidence-based? Intensive Care Med 2010;36:1436-1437.
33. De Jonge E, Schultz MJ, Spanjaard L, et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 2003;362:1011-1016.
34. Nseir S, Martin-Loeches I, Markris D, et al. Impact of appropriate antimicrobial treatment on transition from ventilator-associated tracheobronchitis to ventilatorassociated pneumonia. Crit Care Med 2014. (in press). A prospective observational multicenter study demonstrating that appropriate antibiotic treatment is independently associated with reduced risk of transition from VAT to VAP.
35. Craven DE, Chroneou A, Zias N, Hjalmarson KI. Ventilator-associated tracheobronchitis: the impact of targeted antibiotic therapy on patient outcomes. Chest 2009;135:521-528.
36. Craven DE, Hjalmarson KI. Ventilator-associated tracheobronchitis and pneumonia: thinking outside the box. Clin Infect Dis 2010;51(Suppl 1):S59-66.
37. Craven DE, Hudcova J, Lei Y, et al. Natural history and outcomes of ventilated patients developing heavy bacterial colonization, tracheobronchitis and pneumonia. Abstract, IDSA Meeting, 2012, San Diego, California 2012.
38. Karvouniaris M, Makris D, Manoulakas E, et al. Ventilator-associated tracheobronchitis increases the length of intensive care unit stay. Infect Control Hosp Epidemiol 2013;34:800-808. Increased rates of VAT were frequently identified 18% of patients and the 92% were MDR Gram-negative bacilli. Rates were higher in neurosurgical patients, and VAT was associated with longer ICU stay, but no increase in patient mortality.
39. Simpson VS, Bailey A, Higgerson RA, Christie LM. Ventilator-associated tracheobronchitis in a mixed medical/surgical pediatric ICU. Chest 2013;144:32-38. A well done study examining rates of VAT in a pediatric ICU. Rates of VAT were low, but patients required prolonged ventilation and many patients had a tracheostomy.
40. Craven DE. Ventilator-associated tracheobronchitis (VAT): questions, answers, and a new paradigm? Crit Care 2008;12:157.
41. Abu-Salah T, Dhand R. Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update. Adv Ther 2011;28:728-747.
42. Martin-Loeches I, Papiol E, Almansa R, et al. Intubated patients developing tracheobronchitis or pneumonia have distinctive complement system gene expression signatures in the preinfection period: a pilot study. Med Intensiva 2012;36:257-263.
43. Pandharipande PP, Girard TD, Jackson JC, et al. Long-term cognitive impairment after critical illness. N Engl J Med 2013;369:1306-1316. Excellent study of ICU adult survivors of critical illness due to respiratory failure or shock; 74% had delirum, and 3 months later, 40% of the patients had low global cognition scores and 25% had cognitive impairment 1 year later that was similar to Alzheimer's disease and 33% had impairment similar to traumatic brain injury.
44. Herridge M, Cameron JI. Disability after critical illness. N Engl J Med 2013;369:1367-1369. Editorial comment on reference 3 emphasizing that cognitive dysfunction is prevalent in patients with critical illness.
45. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005;33:2184-2193.
46. Kass EH. Bacteriuria and the diagnosis of infections of the urinary tract; with observations on the use of methionine as a urinary antiseptic. AMA Arch Intern Med 1957;100:709-714.